Your browser doesn't support javascript.
loading
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients.
Teh, Benjamin W; Mikulska, Malgorzata; Averbuch, Dina; de la Camara, Rafael; Hirsch, Hans H; Akova, Murat; Ostrosky-Zeichner, Luis; Baddley, John W; Tan, Ban Hock; Mularoni, Alessandra; Subramanian, Aruna K; La Hoz, Ricardo M; Marinelli, Tina; Boan, Peter; Aguado, Jose Maria; Grossi, Paolo A; Maertens, Johan; Mueller, Nicolas J; Slavin, Monica A.
Affiliation
  • Teh BW; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia. Electronic address: ben.teh@petermac.org.
  • Mikulska M; Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Averbuch D; Pediatric Infectious Diseases, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Hadassah Medical Center, Jerusalem, Israel.
  • de la Camara R; Department of Haematology, Hospital de la Princesa, Madrid, Spain.
  • Hirsch HH; Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland; Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
  • Akova M; Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
  • Ostrosky-Zeichner L; Division of Infectious Diseases, McGovern Medical School, University of Texas, Houston, TX, USA.
  • Baddley JW; Department of Medicine, Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Tan BH; Department of Infectious Diseases, Singapore General Hospital, Singapore.
  • Mularoni A; Department of Infectious Diseases, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS), Palermo, Italy.
  • Subramanian AK; Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • La Hoz RM; Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Marinelli T; Department of Infectious Diseases, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Boan P; Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, WA, Australia; Department of Microbiology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Murdoch, WA, Australia.
  • Aguado JM; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), CIBERINFEC, Universidad Complutense, Madrid, Spain.
  • Grossi PA; Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy.
  • Maertens J; Department of Haematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
  • Mueller NJ; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zürich, Switzerland.
  • Slavin MA; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC, Australia.
Lancet Infect Dis ; 24(1): e59-e68, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37683684
ABSTRACT
Patients can be immunocompromised from a diverse range of disease and treatment factors, including malignancies, autoimmune disorders and their treatments, and organ and stem-cell transplantation. Infections are a leading cause of morbidity and mortality in immunocompromised patients, and the disease treatment landscape is continually evolving. Despite being a critical but preventable and curable adverse event, the reporting of infection events in randomised trials lacks sufficient detail while inconsistency of categorisation and definition of infections in observational and registry studies limits comparability and future pooling of data. A core reporting dataset consisting of category, site, severity, organism, and endpoints was developed as a minimum standard for reporting of infection events in immunocompromised patients across study types. Further additional information is recommended depending on study type. The standardised reporting of infectious events and attributable complications in immunocompromised patients will improve diagnostic, treatment, and prevention approaches and facilitate future research in this patient group.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation Type of study: Clinical_trials Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation Type of study: Clinical_trials Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Type: Article